Chemotherapy agents and hypertension: a focus on angiogenesis blockade.
Two observations highlight the importance of this review. The first observation is that high blood pressure is the most frequent comorbid condition in cancer registries which directly affects the prognosis of the patient. The second observation is that long-term cancer survivors now have a higher risk of cardiovascular disease than of recurrent cancer, and hypertension contributes to this risk. New approaches to cancer chemotherapy disrupt angiogenesis; subjects receiving these agents often have an associated increase in blood pressure. In this article we concentrate on observations published over the past 2 years in this rapidly developing field, outline putative mechanisms and time frames for these prohypertensive effects, and conclude with some management recommendations based on current knowledge.
Department of Medicine, University of Pennsylvania, 3400 Spruce Street, 1 Gibson, Philadelphia, PA 19104, USA.
Manish
M
Jain
Raymond R
RR
Townsend
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000592:standards; D000959:Antihypertensive Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000592:standards / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration; D042442:Vascular Endothelial Growth Factors / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000959:Antihypertensive Agents; D047072:Aromatase Inhibitors; D042442:Vascular Endothelial Growth Factors; D040262:Receptors, Vascular Endothelial Growth Factor